Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I vote that it will be a super-hedgehog, BTH's fav

I think a BRAF mutation drug is more likely, in all. The results coming out of the current BRAF trials are tremendous, however, mutations are developing. And, the indications (think: skin cancer) is a huge market for BRAF.

Hh, unless they show more effectiveness in other indications other than the two indications it REALLY works in, is going to remain a really small but highly effective drug. They need to show results in ligand disease....